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Introduction
Biased agonism, the ability of different ligands for the same 
receptor to selectively activate some signaling pathways 
while blocking others, is now an established paradigm for 
GPCR signaling. Panel A demonstrates a ‘balanced’ agonist, 
signaling through both G protein as well as β-arrestin
pathways. Panel B shows a  pure ‘G protein  biased’ agonist, 
while panel C shows a pure ‘β-arrestin biased’ agonist. 
Objectives and Methods
CXCR3 is an important chemokine receptor that regulates T 
cell-mediated inflammation but has no FDA approved drugs. 
The goal of this study was to measure biased signaling at 
CXCR3 and assess the therapeutic potential of selectively 
targeting certain CXCR3 signaling pathways with biased 
agonists. Biased signaling was measured through 
transcriptomic and phosphoproteomic analyses, as well as 
multidimensional cellular signaling assays. Small molecule 
biased agonists for G protein and β-arrestin were identified. 
Inflammatory properties of the biased agonists were tested in 
a mouse model of T cell allergy.
Results: Endogenous CXCR3 
chemokines are biased
Identification of synthetic biased 
agonists. Small molecule CXCR3 
ligands were assessed for (E) G 
protein activity or (F) β-arrestin
recruitment. (G) VUF10 was 
identified as a β-arrestin-biased 
agonist, while VUF11 was identified 
as a G protein-biased agonist relative 
to CXCL11, a full agonist at both G 
protein and β-arrestin pathways. Both 
agonists have the same affinity for 
CXCR3. *p<0.05 by two-way 
ANOVA
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Chemotactic response of T cells to CXCR3 biased ligands: (H) A β-arrestin
biased agonist caused significantly greater migration of activated CD8+CD44+ 
lymphocytes isolated from WT mice compared to a G-biased agonist, which was 
abrogated in β-arrestin-2 KO and absent in CXCR3 KO lymphocytes. CXCR3+T 
cells from patients displayed a similar pattern of chemotaxis (data not shown). 
Colocalization of CXCR3, β-arr, and CD3 was observed in patients with (I) patch 
test (+) but not (J) (-) skin biopsies for T cell allergy. *p<0.05 by two-way ANOVA
• Endogenous CXCR3 chemokines (CXCL9, CXCL10, and 
CXCL11) are not redundant and induce vastly different 
cellular signaling events.
• Distinct CXCR3 signaling events appear to be 
physiologically relevant, as a CXCR3 β-arrestin-biased 
agonist increased chemotaxis and T cell-mediated 
inflammation relative to a CXCR3 G-biased agonist.
• When designing drugs targeting chemokine receptors, 
looking beyond affinity and G protein signaling pathways 
will likely be necessary for a desired therapeutic benefit.
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(C) Gαi protein signaling assessed through cAMP inhibition at CXCR3. 
(D) β-arrestin signaling at  CXCR3 bioluminescence resonance energy 
transfer (BRET) technology.E
Conclusions
D
(K) Timeline of T cell inflammation model. Mice were 
topically treated with the allergen DNFB (0.5% DNFB 
sensitization on the back, 0.3% elicitation on the ears) and 
CXCR3 ligands at the indicated time points. Change in ear 
thickness was measured. 
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Results: CXCR3 biased agonists 
differentially regulate inflammation
G protein signal β-arrestin signal
G protein signal β-arrestin signal
Bias plot
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Epidermis
I Epidermis
β-arrestin-biased agonist potentiates inflammation in a T 
cell contact hypersensitivity allergy model: (L) Wild-type 
mice topically treated with a β-arrestin-biased agonist, but 
not a G-protein-biased agonist, had a potentiated 
inflammatory response in a mouse model of T cell allergy. 
No potentiation of inflammation by the βarr-biased agonist 
was observed in either (M) β-arrestin-2 KO mice (p=0.77) or 
CXCR3 KO mice (not shown). *p<0.05 by two-way ANOVA
Activated CD8 T cell chemotaxis
β-arrestin KO ear inflammationWT ear inflammation
Green: CXCR3    Red: CD3
Purple: β-arr Blue: Hoechst 
A B C Image adapted from Parham et al 2006. 
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PhosphoproteomicsTranscriptomics 
CXCL9 CXCL10 CXCL11 CXCL9 CXCL10 CXCL11
CXCR3 panomics. Cellular (A) RNA seq and (B) 
phosphoprotein clusters in log(2) scale following 
chemokine stimulation relative to vehicle treatment.
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